We recently published a list of Top 8 AI News Updates Driving Markets Today. In this article, we are going to take a look at where Predictive Oncology Inc. (NASDAQ:POAI) stands against other top AI news updates driving markets today.
The AI race switched gears after Chinese AI startup DeepSeek announced on March 25th that it released a major upgrade to its V3 LLM, intensifying competition with US rivals like OpenAI and Anthropic.
The new model, DeepSeek-V3-0324, is available through the AI development platform Hugging Face as part of the company’s latest efforts to position itself as a leader in the global AI market. DeepSeek claims that the upgrade brings major improvements in reasoning and coding capabilities.
The development comes a day after OpenAI released updates for the Advanced Voice Mode AI feature, which allows for real-time conversation in ChatGPT.
“An OpenAI spokesperson said its new AI voice assistant for paying users is “more direct, engaging, concise, specific, and creative in its answers.”
Elsewhere, fintech Ant Group, backed by Jack Ma, claimed that it was able to develop methods using Chinese chips that trim AI training costs by 20%. This update could hint that Chinese AI developers might be able to gradually reduce reliance on top AI chips manufactured in the US.
We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey’s Q4 2024 database of over 1000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A doctor in a laboratory, overseeing the development of Artificial Intelligence (AI).
Predictive Oncology Inc. (NASDAQ:POAI)
Number of Hedge Fund Holders: N/A
Predictive Oncology Inc. (NASDAQ:POAI) leverages AI and ML to speed up drug discovery and enable drug development to benefit cancer patients. The company claims that its AI platform, PEDAL, can predict the efficacy of medicines on tumor samples with 92% accuracy, which helps in the informed selection of drug/tumor type combinations for in-vitro testing.
On March 25th, Predictive Oncology Inc. (NASDAQ:POAI) said it used its active machine learning platform in partnership with the Natural Products Discovery Core (NPDC) at the University of Michigan Life Sciences Institute to develop predictive models derived from 21 unique compounds. The company said that tumor types — breast, colon and ovary — were selected for testing with the compounds and a well-known anti-cancer drug. After measuring 7% of the possible wet lab experiments, the company’s predictive ML model made confident predictions to cover 73% of all experiments, virtually eliminating up to two years of laboratory testing.
“Three compounds consistently demonstrated strong tumor drug response across all tumor types tested and demonstrated a stronger response than Doxorubicin, a benchmark compound, across tumor types. A fourth drug showed a strong response in the ovary and colon models and three additional compounds demonstrated the most ‘hit responses’ across all three tumor types.”
-said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology Inc.
Overall, POAI ranks 8th on our list of top AI news updates driving markets today. While we acknowledge the potential of POAI as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than POAI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
